CIP
AEGR

Chartwell Investment Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

Chartwell Investment Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-173,025
Closed -$5.55M – 367
2014
Q2 		$5.55M Sell
173,025
-34,845
-17% -$1.3M 0.12% 237
2014
Q1 		$9.6M Buy
207,870
+35,055
+20% +$2.06M 0.2% 187
2013
Q4 		$12.3M Buy
172,815
+79,824
+86% +$6.1M 0.25% 170
2013
Q3 		$7.97M Sell
92,991
-1,420
-2% -$120K 0.18% 208
2013
Q2 		$5.98M Buy
+94,411
New +$5.01M 0.15% 231

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chartwell Investment Partners's AEGR Position: Q3 2014 in Review

Chartwell Investment Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 173,025 shares — an estimated $5.55M sold.

Chartwell Investment Partners first reported a position in AEGR in Q2 2013 and held it in 5 quarters. The position peaked at $12.3M in Q4 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • Chartwell Investment Partners reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Chartwell Investment Partners sold 173,025 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $5.55M.
  • Chartwell Investment Partners first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Chartwell Investment Partners's Aegerion Pharmaceuticals position peaked at $12.3M in Q4 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on Chartwell Investment Partners's 13F filing for Q3 2014, filed 28 Oct 2014.